Prostate Cancer Trial, Recruiting NCT06331013 Sponsor: European Institute of Oncology Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06331013
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old
  • You have been diagnosed with prostate cancer (a specific type called adenocarcinoma, confirmed by a tissue sample)
  • Your prostate cancer falls into the low, intermediate, or high-risk category based on standard medical guidelines
  • Your cancer has not spread to nearby lymph nodes or other parts of the body
  • You are generally well enough to carry out daily activities without significant difficulty (confirm with trial site)
  • You have a good urinary flow rate or a low score on a standard urinary symptoms questionnaire (confirm with trial site)
  • Your prostate gland is not too enlarged (smaller than 100 cc)
  • You have had a special type of prostate MRI scan (called an mpMRI) available for review
  • Your MRI shows fewer than 3 areas of concern in the prostate, and any areas included must meet certain scan scoring requirements (confirm with trial site)
  • You are willing and able to give written consent to take part in the treatment and research

Who may not be able to join:

  • Your blood platelet count is too low (below 75,000), which can affect blood clotting
  • You have a narrowing of the urethra (the tube that carries urine out of the body)
  • You have previously had radiation therapy to the pelvic area
  • You have inflammatory bowel disease or other serious ongoing health conditions
  • You have previously had surgery to remove your prostate
  • You have a hip replacement (prosthesis) on either side

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Barbara Alicja Jereczek, European Institute of Oncology

Phone: +39 0257489037

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
European Institute of Oncology
Registry
ClinicalTrials.gov
Start date
20 February 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Number of Participants with Acute GU and GI toxicities (RTOG); Number of Participants with Late GU and GI toxicities (RTOG); Evaluation of patient-reported toxicity; Evaluation of patient-reported quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov